A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Inclusion Criteria: * Body mass index (BMI) must be ≥ 16.5 kg/m2 and ≤ 35.0 kg/m2; * Female subjects must be of non-childbearing potential; e.g., postmenopausal or pre-menopausal with surgical sterilization; * Male subjects agree to use appropriate contraception; * Adequate blood counts, liver and renal function; * Non-smokers for at least 3 months; * Willing to give written informed consent and are willing to comply with the study requirements; * Subject was born in Japan and has lived outside of Japan for \<10 years, and subject's biological parents and grandparents are fully Japanese and were born in Japan (cohorts 19 and 20). Exclusion Criteria: * Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection; * Subjects with a history of multiple drug allergies or intolerance to SC injection; * History of drug abuse and/or alcohol abuse; * Receiving an investigational agent within 3 months prior to study drug administration; * Considered unfit for the study by the Principal Investigator.